EZ1.F · Enzon Pharmaceuticals, Inc

-

Please sign in to comment on EZ1.F

1 Comment

Admin

4 years ago

Enzon Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 53.6% above its 200 day moving average.

From a valuation standpoint, the stock is 40.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 783.6.

Enzon Pharmaceuticals, Inc's total revenue sank by 30.6% to $34K since the same quarter in the previous year.

Its net income has dropped by 62.6% to $-426K since the same quarter in the previous year.

Finally, its free cash flow fell by 174.0% to $-545K since the same quarter in the previous year.

Based on the above factors, Enzon Pharmaceuticals, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	US2939041081
Industry
Sector

PE Ratio	0.0
Target Price	None
Dividend Yield	0.0%
Beta	0.27
Market Cap	9M

ABOUT

Enzon Pharmaceuticals, Inc

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

EZ1.F · Enzon Pharmaceuticals, Inc

-

Enzon Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Enzon Pharmaceuticals, Inc using a moving average strategy